ATM is altered in 7.49% of colorectal adenocarcinoma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ATR is altered in 3.97% of colorectal adenocarcinoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BARD1 is altered in 2.21% of colorectal adenocarcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF is altered in 11.13% of colorectal adenocarcinoma patients [2].

BRAF is an inclusion eligibility criterion in 5 clinical trials for colorectal adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRAF status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 2/phase 3 (0 open) [3].

BRCA1 is altered in 3.66% of colorectal adenocarcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRCA2 is altered in 8.37% of colorectal adenocarcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRIP1 is altered in 2.53% of colorectal adenocarcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 is altered in 4.36% of colorectal adenocarcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CHEK1 is altered in 1.33% of colorectal adenocarcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CHEK2 is altered in 2.14% of colorectal adenocarcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

DPYD is altered in 0.96% of colorectal adenocarcinoma patients [2].

DPYD is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains DPYD status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is altered in 3.25% of colorectal adenocarcinoma patients [2].

EGFR is an inclusion eligibility criterion in 2 clinical trials for colorectal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

ERBB2 is altered in 4.69% of colorectal adenocarcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 4 clinical trials for colorectal adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and colorectal adenocarcinoma as inclusion criteria, 4 are phase 2 (3 open) [3].

FANCA is altered in 3.69% of colorectal adenocarcinoma patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCB is altered in 1.28% of colorectal adenocarcinoma patients [2].

FANCB is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCC is altered in 1.61% of colorectal adenocarcinoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCD2 is altered in 8.16% of colorectal adenocarcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCE is altered in 2.11% of colorectal adenocarcinoma patients [2].

FANCE is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCF is altered in 1.53% of colorectal adenocarcinoma patients [2].

FANCF is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCG is altered in 1.4% of colorectal adenocarcinoma patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCI is altered in 2.89% of colorectal adenocarcinoma patients [2].

FANCI is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCL is altered in 1.5% of colorectal adenocarcinoma patients [2].

FANCL is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCM is altered in 6.69% of colorectal adenocarcinoma patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS is altered in 0.67% of colorectal adenocarcinoma patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is altered in 44.33% of colorectal adenocarcinoma patients [2].

KRAS is an inclusion eligibility criterion in 12 clinical trials for colorectal adenocarcinoma, of which 10 are open and 2 are closed. Of the trials that contain KRAS status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 6 are phase 2 (6 open), and 2 are phase 3 (2 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MET is altered in 2.14% of colorectal adenocarcinoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is altered in 2.07% of colorectal adenocarcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NBN is altered in 2.63% of colorectal adenocarcinoma patients [2].

NBN is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS is altered in 4.72% of colorectal adenocarcinoma patients [2].

NRAS is an inclusion eligibility criterion in 8 clinical trials for colorectal adenocarcinoma, of which 8 are open and 0 are closed. Of the trials that contain NRAS status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), and 1 is phase 3 (1 open) [3].

PALB2 is altered in 2.81% of colorectal adenocarcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

POLE is altered in 5.69% of colorectal adenocarcinoma patients [2].

POLE is an inclusion eligibility criterion in 2 clinical trials for colorectal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PTEN is altered in 6.23% of colorectal adenocarcinoma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD50 is altered in 2.78% of colorectal adenocarcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51 is altered in 0.51% of colorectal adenocarcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51B is altered in 0.29% of colorectal adenocarcinoma patients [2].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51C is altered in 0.79% of colorectal adenocarcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD51D is altered in 0.82% of colorectal adenocarcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAD54L is altered in 1.73% of colorectal adenocarcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SLX4 is altered in 4.56% of colorectal adenocarcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is altered in 68.53% of colorectal adenocarcinoma patients [2].

TP53 is an inclusion eligibility criterion in 2 clinical trials for colorectal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

UGT1A1 is an inclusion eligibility criterion in 2 clinical trials for colorectal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain UGT1A1 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].